SCYX - Scynexis launches late-stage oral ibrexafungerp study in invasive candidiasis

Scynexis (NASDAQ:SCYX) announces initiation of a Phase 3 study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a step-down therapy for patients with invasive candidiasis (IC) and/or candidemia compared to oral fluconazole. Shares up 1.9% premarket at $6.50. Approx. 220 patients will be enrolled and randomized in the study. The primary objective of the study is to determine whether treatment of IC with IV echinocandins followed by oral ibrexafungerp is as effective as treatment with IV echinocandins followed by oral fluconazole, the current standard of care. The primary end point will be all-cause mortality at 30 days after initiation of antifungal therapy. There will also be an open label arm to evaluate oral ibrexafungerp compared to the best available therapy in patients with azole-resistant infections.

For further details see:

Scynexis launches late-stage oral ibrexafungerp study in invasive candidiasis